研究發(fā)現(xiàn)：血漿磷酸化tau181蛋白可用于預(yù)測(cè)阿爾茨海默氏癥
2020-03-03
來(lái)源：小柯機(jī)器人
瑞典隆德大學(xué)Oskar Hansson、Shorena Janelidze等研究人員合作揭示，血漿磷酸化tau181（P-tau181）蛋白與阿爾茨海默氏癥（AD）的關(guān)聯(lián)性。相關(guān)論文于2020年3月2日在線發(fā)表于《自然—醫(yī)學(xué)》。
研究人員在三個(gè)隊(duì)列中研究了血漿P-tau181，共有589名個(gè)體，包括無(wú)認(rèn)知障礙的參與者以及輕度認(rèn)知障礙（MCI）、AD癡呆和非AD神經(jīng)退行性疾病的患者。
血漿P-tau181在臨床前AD中升高，在MCI和癡呆期進(jìn)一步升高。它與CSF P-tau181相關(guān)，并預(yù)測(cè)出陽(yáng)性Tau正電子發(fā)射斷層掃描（PET）（曲線下面積（AUC）= 0.87–0.91，不同的大腦區(qū)域）。
血漿P-tau181將AD癡呆癥與非AD神經(jīng)退行性疾病區(qū)別開來(lái)，其準(zhǔn)確性與Tau PET和CSF P-tau181相似（AUC = 0.94-0.98），并在尸檢證實(shí)的隊(duì)列中檢測(cè)到AD神經(jīng)病理學(xué)。血漿高P-tau181與認(rèn)知障礙者和MCI患者AD癡呆癥的發(fā)展有關(guān)。
總之，血漿P-tau181是AD的一種非侵入性診斷和預(yù)后生物標(biāo)志物，可能在臨床實(shí)踐和試驗(yàn)中有用。
據(jù)悉，血漿P-tau181蛋白在AD中可能增加，但其在鑒別診斷和預(yù)后方面的用途尚不清楚。
附：英文原文
Title: Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia
Author: Shorena Janelidze, Niklas Mattsson, Sebastian Palmqvist, Ruben Smith, Thomas G. Beach, Geidy E. Serrano, Xiyun Chai, Nicholas K. Proctor, Udo Eichenlaub, Henrik Zetterberg, Kaj Blennow, Eric M. Reiman, Erik Stomrud, Jeffrey L. Dage, Oskar Hansson
Issue&Volume: 2020-03-02
Abstract: Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer’s disease (AD), but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P-tau181 in three cohorts, with a total of 589 individuals, including cognitively unimpaired participants and patients with mild cognitive impairment (MCI), AD dementia and non-AD neurodegenerative diseases. Plasma P-tau181 was increased in preclinical AD and further increased at the MCI and dementia stages. It correlated with CSF P-tau181 and predicted positive Tau positron emission tomography (PET) scans (area under the curve (AUC)=0.87–0.91 for different brain regions). Plasma P-tau181 differentiated AD dementia from non-AD neurodegenerative diseases with an accuracy similar to that of Tau PET and CSF P-tau181 (AUC=0.94–0.98), and detected AD neuropathology in an autopsy-confirmed cohort. High plasma P-tau181 was associated with subsequent development of AD dementia in cognitively unimpaired and MCI subjects. In conclusion, plasma P-tau181 is a noninvasive diagnostic and prognostic biomarker of AD, which may be useful in clinical practice and trials.
DOI: 10.1038/s41591-020-0755-1
Source: https://www.nature.com/articles/s41591-020-0755-1
聲明：本文版權(quán)歸原作者所有，轉(zhuǎn)載文章僅為傳播更多信息，如作者信息標(biāo)記有誤，或侵犯您的版權(quán)，請(qǐng)聯(lián)系我們，我們將在及時(shí)修改或刪除內(nèi)容，聯(lián)系郵箱：marketing@360worldcare.com
